The FDA has approved Pfizer’s trastuzumab-qyyp (Trazimera), a biosimilar referencing Herceptin.
The FDA has approved Pfizer’s trastuzumab-qyyp (Trazimera), a biosimilar referencing Herceptin.
"This is an important milestone in the [United States] which both adds to our growing portfolio of oncology treatments and has the potential to improve access to cancer care,” said Andy Schmeltz, global president of Pfizer Oncology, in a statement. “We are proud to be able to offer treatment options that can help address the diverse needs of patients.”
Pfizer’s data package for the biosimilar included findings from the comparative clinical trial for the biosimilar, REFLECTIONS B327-02. The study found that, in patients receiving trastuzumab and paclitaxel as first-line treatment for HER2-positive metastatic breast cancer, the biosimilar showed similar efficacy, safety, immunogenicity, and pharmacokinetics (PK) to the EU-licensed reference drug. The study met its primary objective for equivalence in the objective response rate (ORR) for the biosimilar versus the reference, with the risk ratio of ORR of 0.940 (95% CI, 0.842-1.049) falling within the prespecified equivalence margin of 0.8 to 1.25.
A supplemental study of the biosimilar as neoadjuvant therapy in combination with docetaxel and carboplatin, REFLECTIONS B327-04, found no clinically meaningful differences between the biosimilar and the EU-licensed reference in terms of efficacy, safety, immunogenicity, and noninferiority in terms of PK.
The approval for Trazimera, which also earned EU authorization in July 2018, comes after Pfizer first received a Complete Response Letter from the FDA in April 2018. The company said at the time that the FDA had asked for “additional technical information,” but did not request additional clinical information or safety data.
Trazimera is the fourth trastuzumab biosimilar, following the FDA’s approval of Ontruzant, Herzuma, and Ogivri, none of which have launched in the United States.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.